Tag Archives: Obamacare

US Healthcare Reform: A Pharm Exec Digest Special

This month’s special issue of Pharm Exec Global Digest looks at Dealing with the “side effects” of Obamacare The “value” of Rxs under Obamacare The escalating cost of US oncology care And more… Click here to read the issue.
Posted in Global, healthcare, Regulatory | Also tagged , , | Leave a comment

Five Measures to Cope with the Side Effects of Health Reform

By Sydney Rubin. With more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before. People previously rejected by insurers due to pre-existing conditions […]
Posted in Guest Blog, healthcare, Op-Ed, pricing, Regulatory | Also tagged , , | Leave a comment

Physicians Won’t Change Their Practices Without Worthwhile Incentives

By Mark Wagar. (This blog first appeared on Managed Healthcare Executive.) There is more collaboration than ever between payers and providers in the drive to provide high-quality, cost-effective care to diverse populations across the United States. According to a January 2014 Centers for Medicare and Medicaid Services (CMS) report, the accountable care organization (ACO) model is […]
Posted in Guest Blog, healthcare, Regulatory | Also tagged , , , , , | Leave a comment

Things Looking Up for Obamacare, But New HHS Chief Faces Tough 2015

This blog previously ran on Managed Healthcare Executive. The Obama administration received a substantial amount of good news last month. Not only did 8 million individuals enroll in qualified health plans, millions more joined Medicaid or obtained coverage through private markets. Additionally, health reform will cost $100 billion less than anticipated, according to the Congressional […]
Posted in healthcare, Op-Ed, Regulatory | Also tagged , , , | Leave a comment

Obamacare's "Unacceptable" Rx Copays

by Tom Norton We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth […]
Posted in Biotech, Guest Blog, healthcare, leadership, Legal, Market Access, Strategy | Also tagged , , , , , , | 2 Comments
  • Categories

  • Meta